American Association for Cancer Research Welcomes New Board of Directors, Nominating Committee Members

PHILADELPHIA — The members of the American Association for Cancer Research (AACR) have elected five members to serve on the AACR Board of Directors for the 2014-2017 term and four members to serve on the Nominating Committee for the 2014-2016 term. They will assume their roles at the AACR Annual Meeting 2014, to be held in San Diego, Calif., April 5-9.

The following five scientists were elected to the AACR Board of Directors:

James P. Allison, Ph.D., is chair of the Department of Immunology, executive director of the Immunology Platform, associate director of the Center for Cancer Immunology Research, deputy director of the David H. Koch Center for Applied Research in Genitourinary Cancer, and the Lilian H. Smith distinguished chair of immunology at The University of Texas MD Anderson Cancer Center in Houston. He is a leader of the Stand Up To Cancer (SU2C)-Cancer Research Institute Dream Team: Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy.

He is currently deputy editor of Cancer Immunology Research, a scientific editor of Cancer Discovery, and a member of the SU2C-Melanoma Research Alliance Joint Scientific Advisory Committee and the AACR Clinical Research and Experimental Therapeutics Awards Committee.

Ronald M. Evans, Ph.D., is a professor at the Gene Expression Laboratory and March of Dimes chair in molecular and developmental biology at the Salk Institute for Biological Studies in La Jolla, Calif.; investigator with the Howard Hughes Medical Institute; and adjunct professor of biology and pharmacology at the University of California, San Diego (UCSD).

He is currently deputy editor of Cancer Prevention Research, and a member of the Education and Training Committee and the Council of Scientific Advisors.

Scott M. Lippman, M.D., is director of the UCSD Moores Cancer Center; senior associate dean and associate vice chancellor for cancer research and care at UCSD Health Sciences; professor of medicine and Chugai Pharmaceutical chair in cancer research at UCSD; adjunct professor at the Salk Institute and the Sanford-Burnham Medical Institute in La Jolla, Calif.; and adjunct professor at The University of Texas MD Anderson Cancer Center in Houston.

He is currently editor-in-chief of Cancer Prevention Research, chair of the Cancer Prevention Committee, and a member of the 2012 and 2014 Annual Meeting Clinical Trials Committees.

Guillermina Lozano, Ph.D., is a professor and chair of the Department of Genetics, co-director of the genetically engineered mouse facility, co-director of the Center for Genetics and Genomics, co-director of the sequencing and microarray facility, and co-director of the Cancer Genetics and Epigenetics Program at The University of Texas MD Anderson Cancer Center in Houston; and a member of The University of Texas Graduate School of Biomedical Sciences in Houston.

She is currently a member of the SU2C Scientific Advisory Committee, the Molecular Cancer Research editorial board, and the Publications Committee.

M. Celeste Simon, Ph.D., is a professor in the Department of Cell and Development Biology and scientific director and investigator at the Abramson Family Cancer Research Institute, University of Pennsylvania, in Philadelphia; and an investigator with the Howard Hughes Medical Institute.

She is currently chair of the AACR special conference on Cellular Heterogeneity in the Tumor Microenvironment and a member of the Tumor Microenvironment Committee and the Special Conferences Committee.

The following four scientists were elected to the AACR Nominating Committee:

René Bernards, Ph.D., is head of the Division of Molecular Carcinogenesis at the Netherlands Cancer Institute in Amsterdam; professor of molecular carcinogenesis at Utrecht University in Utrecht, Netherlands; and founder and chief scientific officer of Agendia BV in Amsterdam. He is a leader of the SU2C-Dutch Cancer Society (KWF Kankerbestrijding) Sta Op Tegen Kanker Translational Cancer Research Grant: Prospective Use of DNA-guided Personalized Cancer Treatment.

He is currently a scientific editor of Cancer Discovery, an editorial board member of Molecular Cancer Research, and a member of the AACR Laboratory Research Awards Committee.

Joe W. Gray, Ph.D., is Gordon Moore endowed chair in the Department of Biomedical Engineering, director of the Center for Spatial Systems Biomedicine, and associate director for translational research at the Knight Cancer Institute at Oregon Health & Science University in Portland; and a member of the graduate faculty and professor in the Department of Radiation Medicine in the School of Medicine at Oregon Health & Science University. He is a leader of the SU2C Dream Team: An Integrated Approach to Targeting Breast Cancer Molecular Subtypes and Their “Resistance” Phenotypes.

He is currently an editorial board member of Molecular Cancer Research and a member of the Annual Meeting Program Committee, the Tumor Microenvironment Working Group, the AACR-Women in Cancer Research Charlotte Friend Memorial Lectureship Committee, and the AACR Team Science Award Committee.

Lillian L. Siu, M.D., is a professor in the faculty of medicine at the University of Toronto in Toronto, Ontario, Canada; director of the drug development fellowship program, director of the phase I program, co-director of the Robert and Maggie Bras and Family drug development program, and staff medical oncologist at Princess Margaret Hospital in Toronto; and tier I research chair in experimental therapeutics at Cancer Care Ontario in Toronto.

She is chair of the Landon Foundation-AACR INNOVATOR Award for International Collaboration in Cancer Research Committee, a scientific editor of Cancer Discovery, and a member of the Annual Meeting Program Committee and the AACR-Women in Cancer Research Council.

Margaret R. Spitz, M.D., M.P.H., is a professor at the Dan L. Duncan Cancer Center at Baylor College of Medicine in Houston.

She is currently a scientific editor of Cancer Discovery, an editorial adviser for Cancer Today, an editorial board member of Cancer Epidemiology, Biomarkers & Prevention, and a member of the Behavioral Science in Cancer Research Scientific Working Group, the Pediatric Cancer Working Group, the Chemistry in Cancer Research Working Group, and the Molecular Epidemiology Working Group.

Advertisement